Sophorolipids in sepsis: Antiinflammatory or antibacterial?

Critical Care Medicine

Volumn 34, Issue 1, 2006, Pages 258-259

  Napolitano, Lena M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Abdominal sepsis; Cytokine; Lipopolysaccharide; Septic shock; Sophorolipids

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; CPL 1 LYSOZYME; ENZYME; GLYCOLIPID; PAL AMIDASE; PEPTIDE DERIVATIVE; PROBIOTIC AGENT; SOPHOROLIPID; UNCLASSIFIED DRUG;

ANTHRAX; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BACILLUS ANTHRACIS; BACTERIAL INFECTION; CANCER; CANDIDA; CYTOKINE PRODUCTION; EDITORIAL; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PYOGENES;

EID: 29744443125     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000196082.26483.F0     Document Type: Editorial

References (14)

1. Gorin APJ, Spencer JFT, Tulloch AP: Hydroxy fatty acid glycosides of sophorose from Torulopsis magnoliae. Can J Chem 1961; 39:846-895
2. Bluth MH, Kandil E, Mueller CM, et al: Sophorolipids block lethal effects of septic shock in rats in a cecal ligation and puncture model of experimental sepsis. Crit Care Med 2006; 34:188-195
3. Vyas D, Javadi P, Dipasco PJ, et al: Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die based upon high IL-6 levels. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1048-R1053
4. Horino T, Matsumoto T, Uramtsu M, et al: Interleukin-1-deficient mice exhibit high sensitivity to gut-derived sepsis caused by Pseudomonas aeruginosa. Cytokine 2005; 30:339-346
5. Ashare A, Powers LS, Butler NS, et al: Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am J Physiol Lung Cell Mol Phsyiol 2005; 288:L633-L640
6. López R, Garcia E: Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage. FEMS Microbiol Rev 2004; 28:553-580
7. Loeffler J, Nelson D, Fischetti VA: Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294:2170-2172
8. Loessner MJ: Bacteriophage endolysins: Current state of research and applications. Curr Opin Microbiol 2005; 8:480-487
9. Schuch R, Nelson D, Fischetti VA: A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002; 418:884-889
10. Lopez R: Streptococcus pneumoniae and its bacteriophages: One long argument. International Microbiology 2004; 7:163-171
11. Jado I, López R, Garcia E, et al: Spanish Pneumococcal Infection Study Network. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52:967-973
12. Oggioni MR, Iannelli F, Ricci S, et al: Antibacterial activity of a competence-stimulating peptide in experimental sepsis caused by Streptococcus pneumoniae. Antimicrob Agents Chemother 2004; 48:4725-4732
13. Lucas A, McFadden G: Secreted immunomodulatory viral proteins as novel biotherapeutics. J Immunol 2004; 173:4765-4774
14. Punj V, Saint-Dic D, Daghfal S, et al: Microbial-based therapy of cancer: A new twist to age old practice. Cancer Biol Ther 2004;3:708-714